Table 1

The effect of catheter segments or tissue factor (RecombiPlasTin) on clotting times in normal or fVII-, fXI-, or fXII-deficient platelet-poor plasma

Type of plasma/conditionTime to clot, s
Normal  
    Control 971 ± 92 
    Catheter 352 ± 22* 
    RecombiPlasTin 102 ± 1* 
    Catheter + RecombiPlasTin 93 ± 3* 
fVII-deficient  
    Control 782 ± 35 
    Catheter 387 ± 27* 
    RecombiPlasTin 514 ± 30* 
    Catheter + RecombiPlasTin 320 ± 28* 
fXI-deficient  
    Control > 2500 
    Catheter > 2500 
    RecombiPlasTin 136 ± 38* 
    Catheter + RecombiPlasTin 140 ± 45* 
f XII-deficient  
    Control 2467 ± 306 
    Catheter 1625 ± 532 
    RecombiPlasTin 133 ± 40* 
    Catheter + RecombiPlasTin 131 ± 38* 
Type of plasma/conditionTime to clot, s
Normal  
    Control 971 ± 92 
    Catheter 352 ± 22* 
    RecombiPlasTin 102 ± 1* 
    Catheter + RecombiPlasTin 93 ± 3* 
fVII-deficient  
    Control 782 ± 35 
    Catheter 387 ± 27* 
    RecombiPlasTin 514 ± 30* 
    Catheter + RecombiPlasTin 320 ± 28* 
fXI-deficient  
    Control > 2500 
    Catheter > 2500 
    RecombiPlasTin 136 ± 38* 
    Catheter + RecombiPlasTin 140 ± 45* 
f XII-deficient  
    Control 2467 ± 306 
    Catheter 1625 ± 532 
    RecombiPlasTin 133 ± 40* 
    Catheter + RecombiPlasTin 131 ± 38* 

Plasma was incubated for 10 minutes at 37°C in the presence of PCI catheter segments before the addition of CaCl2 to 20mM with or without a 1/1500-fold dilution of RecombiPlasTin. As a control, clotting was monitored in the absence of catheters or RecombiPlasTin. Absorbance was monitored up to a maximum of 2500 seconds in a plate reader, and time to clot was determined as the time to one-half maximal absorbance. Results reflect the mean ± SD of ≥ 3 determinations.

*

P < .05 compared with the respective controls.

or Create an Account

Close Modal
Close Modal